Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Nano vaccine for hepatitis B shows promise for third world

14.08.2008
Nanoemulsion could save more lives by removing current vaccines' drawbacks

Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing areas. The disease and its complications cause an estimated 1 million deaths globally each year.

In many poor countries, refrigerated conditions required for the current vaccines are costly and hard to come by. It's often difficult in the field to keep needles and syringes sterile. The need to have people return for the three shots currently required also limits success.

Now, a new vaccine that avoids these drawbacks has moved a step closer to human trials. Health researchers hope it will make it possible to immunize large numbers of children and adults in Africa, Asia and South America efficiently and safely.

Scientists at the Michigan Nanotechnology Institute for Medicine and Biological Sciences at the University of Michigan report that a novel, needle-less method for getting an immunity-stimulating agent into the body has proved non-toxic and able to produce strong, sustained immune responses in animal studies. The vaccine is based on a super-fine emulsion of oil, water and surfactants placed in the nose.

The research was supported by the Grand Challenges in Global Health initiative, which is funded by the Bill & Melinda Gates Foundation, the Foundation for the National Institutes of Health, the Wellcome Trust and the Canadian Institutes of Health Research. The findings appear online in the journal PLoS ONE.

The nanoemulsion represents a new delivery method for an antigen already used in existing hepatitis B vaccines to activate the body's immune defenses.

"Our results indicate that needle-free nasal immunization, using a combination of nanoemulsion and hepatitis B antigen, could be a safe and effective hepatitis B vaccine, and also provide an alternative booster method for existing vaccines," says James R. Baker, Jr., M.D., the study's senior author and director of the institute. He also is Ruth Dow Doan Professor and allergy division chief in the U-M Department of Internal Medicine.

The nanoemulsion is made up of soybean oil, alcohol, water and detergents emulsified into droplets less than 400 nanometers in diameter.

The study suggests that the new type of hepatitis B vaccine will not have rigid cold storage requirements and could require fewer administrations than current vaccines, which require three shots given over a period of six months. Protective immunity with the new vaccine required only two immunizations in animals. The vaccine also avoids the risk of spreading needle-borne infections.

The nanoemulsion vaccine also avoids the temporary pain and redness that results after people get shots with the current vaccines, in which an irritating compound, alum, is used as an adjuvant, or enhancer of a vaccine's effect. There was no local inflammation at the nasal site of administration with the new vaccine.

This finding may be significant, because one of the major concerns for nasal administration of vaccines is that they can find their way to the olfactory bulb in the brain and cause side effects, says Paul E. Makidon, D.V.M., co-first author of the study and a U-M research fellow. "Our studies, however, indicate no inflammation and no evidence of the vaccine in the olfactory bulb," he says.

Baker's team has published earlier studies affirming the promise of nasal nanoemulsions as a strategy for smallpox, influenza, anthrax and HIV vaccines. The nanoemulsion technology is patented by U-M and licensed to Ann Arbor-based NanoBio Corporation. Baker is a founder and equity holder of NanoBio.

Research details:

The research team determined effective doses of the antigen and nanoemulsion. In results obtained in mice, rats and guinea pigs, the nanoemulsion vaccine proved effective at producing three types of immunity: systemic, mucosal and cellular. Further toxicity studies in rodents and dogs showed the vaccine was safe and well-tolerated.

The vaccine was as effective as current hepatitis B vaccines in eliciting systemic protective antibodies in the blood of animals. The nanoemulsion acted as an effective adjuvant, without the need for a traditional adjuvant or inflammatory compound as in the current hepatitis B vaccines.

In addition, the nanoemulsion vaccine produced sustained cellular immunity in Th1 cells, which could make the vaccine useful in treating people with chronic hepatitis B whose own cellular immune responses are inadequate.

The animals given the nasal nanoemulsion in the study also activated a third type of immunity, mucosal immunity, which is gaining recognition among immunologists as a key first-line response to infectious agents in diseases such as hepatitis B where mucosal tissues are involved in transmission. Baker and his team found the same effect of activating mucosal immunity that was seen in their previous studies of other nanoemulsion-based vaccines.

The researchers tested whether the vaccine could remain stable and effective even if not refrigerated. They found the nanoemulsion vaccine retained its effectiveness for six months when kept at 25 degrees Celsius (77 degrees Fahrenheit), and even was stable and effective for six weeks at 40 degrees C (104 degrees F). This suggests that refrigeration will not be needed for the final distribution of the vaccine in developing countries, making it easier to vaccinate underserved people.

Current studies are focused on developing the preclinical data required to enter human trials, Baker says. The researchers hope that the first human trial can begin within a year.

Anne Rueter | EurekAlert!
Further information:
http://www.umich.edu
http://dx.plos.org/10.1371/journal.pone.0002954

Further reports about: Chronic hepatitis B Nanoemulsion hepatitis B vaccines

More articles from Health and Medicine:

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Scientist invents way to trigger artificial photosynthesis to clean air

26.04.2017 | Materials Sciences

Ammonium nitrogen input increases the synthesis of anticarcinogenic compounds in broccoli

26.04.2017 | Agricultural and Forestry Science

SwRI-led team discovers lull in Mars' giant impact history

26.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>